Invention Application
- Patent Title: CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE
- Patent Title (中): 磷酸西他汀的结晶形式
-
Application No.: PCT/US2009/038187Application Date: 2009-03-25
-
Publication No.: WO2009120746A2Publication Date: 2009-10-01
- Inventor: PERLMAN, Nurit , RAMATY, Revital , ABRAMOV, Mili , FINKELSTEIN, Nina , LANCRY, Eli , ASIS, Shay , MITTELMAN, Ariel
- Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , PERLMAN, Nurit , RAMATY, Revital , ABRAMOV, Mili , FINKELSTEIN, Nina , LANCRY, Eli , ASIS, Shay , MITTELMAN, Ariel
- Applicant Address: 5 Basel Street P.O. Box 3190 49131 Petah Tiqva IL
- Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD.,TEVA PHARMACEUTICALS USA, INC.,PERLMAN, Nurit,RAMATY, Revital,ABRAMOV, Mili,FINKELSTEIN, Nina,LANCRY, Eli,ASIS, Shay,MITTELMAN, Ariel
- Current Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD.,TEVA PHARMACEUTICALS USA, INC.,PERLMAN, Nurit,RAMATY, Revital,ABRAMOV, Mili,FINKELSTEIN, Nina,LANCRY, Eli,ASIS, Shay,MITTELMAN, Ariel
- Current Assignee Address: 5 Basel Street P.O. Box 3190 49131 Petah Tiqva IL
- Agency: BIRDE, Patrick, J. et al.
- Priority: US61/189,128 20080814; US61/201,860 20081215; US61/070,866 20080325; US61/154,491 20090223; US61/134,598 20080710; US61/137,489 20080730; US61/090,736 20080821; US61/091,759 20080826; US61/092,555 20080828; US61/190,868 20080902; US61/191,933 20080911; US61/201,304 20081208
- Main IPC: C07D487/04
- IPC: C07D487/04
Abstract:
A Sitagliptin phosphate characterized by data selected from the group consisting of: a powder XRD pattern with peaks at 4.7, 13.5, 17.7, 18.3, and 23.7 ±0.2 degrees two theta; a powder XRD pattern with peaks at about 4.7, 13.5, and 15.5 ±0.2 degrees two theta and at least another two peaks selected from the following list: 14.0, 14.4, 18.3, 19.2, 19.5 and 23.7 ±0.2 degrees two theta; and a powder XRD pattern with peaks at about 13.5, 19.2, and 19.5 ±0.2 degrees two theta and at least another two peaks selected from the following list: 4.7, 14.0, 15.1, 15.5, 18.3, and 18.7 ±0.2 degrees two theta; a powder XRD pattern with peaks at about 13.5, 15.5, 19.2, 23.7, and 24.4 ±0.2 degrees two theta; and a powder XRD pattern with peaks at about 4.65, 13.46, 17.63, 18.30, and 23.66 ±0.10 degrees two theta, processes for preparing said Sitagliptin crystalline form, and pharmaceutical compositions thereof, are provided.
Information query
